The influence of genetic variation on late effects in childhood cancer survivors: An updated systematic review [0.03%]
儿童癌症幸存者后期影响的遗传易感性综述研究更新报告
Melissa Bolier,Stefanie J M van Leerdam,Linda Broer et al.
Melissa Bolier et al.
Introduction: Variation in the prevalence and severity of late effects in similarly treated childhood cancer survivors suggests a role for genetic susceptibility. We aimed to provide an overview of genetic factors associa...
Comparison of regional differences in safety and efficacy of CAR-T therapy for hematologic malignancies in a real-world setting: a systematic review and meta-analysis [0.03%]
基于真实世界队列的CAR-T治疗血液系统恶性肿瘤的安全性及有效性的地区差异比较：系统综述和荟萃分析
Zhihan Chen,Wenjng Luo,Yun Kang et al.
Zhihan Chen et al.
Background: Chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment landscape of patients with hematologic malignancies. Nevertheless, geographic regions may lead to various outcomes, including cytoki...
Bystander effect in antibody-drug conjugates: Navigating the fine line in tumor heterogeneity [0.03%]
抗体药物偶联物中的旁观者效应：在肿瘤异质性中寻找平衡点
Yiming Wang,Xi Cheng,Xuan Li et al.
Yiming Wang et al.
Antibody-drug conjugates (ADCs) represent a transformative advancement in targeted cancer therapy by combining monoclonal antibodies with cytotoxic payloads. A critical yet underexplored feature of ADCs is the bystander effect, wherein rele...
Adjuvant Immunotherapy in High-Risk Renal Cell Carcinoma: Indications, Limitations, and Perspectives. A Consensus Statement from the GIOTTO Uro-Oncology Group [0.03%]
高风险肾细胞癌辅助免疫治疗的指征、局限性及展望：GIOTTO泌尿生殖系肿瘤工作组共识声明
Giandomenico Roviello,Federico Paolieri,Martina Catalano et al.
Giandomenico Roviello et al.
Renal cell carcinoma (RCC) is often diagnosed at a localized stage and treated with surgery. However, up to 40% of patients may experience recurrence despite complete resection. The introduction of immune checkpoint inhibitors, particularly...
Immune checkpoint inhibitor-related thrombocytopenia: Current status and future perspectives [0.03%]
免疫检查点抑制剂相关血小板减少症：现状与未来展望
Peng-Fei Zhang,Xiao-Cui Ye,Xuan-Qiong Shi et al.
Peng-Fei Zhang et al.
Immune checkpoint inhibitors (ICIs) have achieved significant success in cancer treatment, yet their associated adverse effects, particularly ICI-related thrombocytopenia (irTCP), are gaining increasing attention. IrTCP leads to serious com...
Immune Checkpoint Inhibitors With Trastuzumab and Chemotherapy in Advanced HER2-Positive Gastric Cancer: A Systematic Review and Meta-Analysis [0.03%]
抗PD-(L)1药物联合曲妥珠单抗和化疗治疗HER2阳性晚期胃癌：系统评价和 meta 分析
Francisco Cezar Aquino de Moraes,Luis Henrique Rios Moreira Rego,Felipe Alves de Paiva et al.
Francisco Cezar Aquino de Moraes et al.
Background: Gastric and gastroesophageal junction (GEJ) cancers with HER2 overexpression have limited durable responses to standard HER2-targeted therapies. Adding immune checkpoint inhibitors (ICIs) to anti-HER2 regimens...
Gut microbiota and chemoradiotherapy response in rectal cancer: biomarker opportunities [0.03%]
肠道微生物群和局部晚期直肠癌的化学放射治疗反应：生物标志物机会
Christophe Taoum,Amandine Devaux,Philippe Rouanet et al.
Christophe Taoum et al.
The gut microbiota is increasingly recognized as a key factor in rectal carcinogenesis. This review synthesizes current clinical and preclinical evidence linking specific microbial signatures, such as Fusobacterium nucleatum, Duodenibacillu...
Could immune checkpoints PD-1/PD-L1, PD-L2 and CTLA-4 be valuable in the spontaneous canine model of breast cancer? [0.03%]
犬自发性乳腺癌中PD-1/PD-L1、PD-L2和CTLA-4免疫检查点的作用研究
Marta Monteiro,Marta Santos,Andreia Santos
Marta Monteiro
Immunotherapy has emerged as an auspicious new therapeutic modality in oncology, with immune checkpoint inhibitors showing promising results on several malignancies. Immune checkpoint molecules, such as PD-1 and its ligands (PD-L1 and PD-L2...
From Innate Power to Intelligent Design: The Evolution of NK Cell-Based Cancer Immunotherapy [0.03%]
从天然杀伤力到理性设计——基于NK细胞的肿瘤免疫治疗的发展历程
Israth Jahan Tuhin,Hong Jia Zhu,Masuma Akter Monty et al.
Israth Jahan Tuhin et al.
Natural killer (NK) cells have emerged as a promising platform for cancer immunotherapy due to their intrinsic cytotoxicity, lack of antigen restriction, and minimal risk of graft-versus-host disease, enabling the development of safe and sc...
The Role of GPI-Anchored LY6/uPAR Family Proteins in Connecting Membrane Microdomains with Immune Regulation and Diseases [0.03%]
糖基磷脂酰肌醇锚定的LY6/urokinase型蛋白酶激活受体家族蛋白质在连接膜微域与免疫调节和疾病中的作用
Jingyi Wen,Le Wu,Shangwei Zhong et al.
Jingyi Wen et al.
Glycosylphosphatidylinositol (GPI)-anchored LY6/uPAR family proteins are structurally conserved yet functionally diverse regulators of immune signaling. Defined by a characteristic three-finger LY6/uPAR (LU) domain and preferential localiza...